[{"arm_notes": "", "treatment_id": null, "treatment_name": "Patients in the active arm of the trial will be receiving open-label Losartan in a dosage titrated with regards to blood pressure and renal function up to a maximum of 100 mg once daily. Active treatment with Losartan will continue until death or discharge from hospital; or for a maximum of 28 days post-randomization. The starting dose will be 25 mg for patients with a systolic blood pressure of 120 - 130 mmHg at randomization and 50 mg for patients with a systolic blood pressure of > 140 mmHg. Patients randomized to the control group will receive standard treatment. There will be no placebo intervention. If blood pressure medication is warranted according to existing guidelines a non-ACEi or ARB medication should be chosen. The randomization will be performed using an online randomization system; in a 1:1 ratio; with a pre-generated random sequence in blocks of random size from 2 to 6.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 744, "treatment_name": "Losartan", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]